Clinical Trial Update: Sym004 Versus Futuximab or Modotuximab in Patients With mCRC [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing Sym004 with Futuximab or Modotuximab in metastatic colorectal cancer was terminated with posted results in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Colorectal Cancer Metastasis

Drugs mentioned

• Futuximab (futuximab)
• Modotuximab (modotuximab)
• Sym004

Snippet

Sponsor: Symphogen A/S | Conditions: Metastatic Colorectal Cancer, Colorectal Cancer Metastatic | Phase 2 | Status: TERMINATED | Results posted: 2020-01-14